RxDoctor Payments Data

Allyssa Cardona, PA

Physician Assistant · Asheville, NCNPI 1285266635

Payments from drug & device makers

$12,221in general payments, 2019–2025

Across 588 payments — averaging $20.78 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • MDD US Operations, LLC$788
  • Novartis$621
  • UCB, Inc.$607
  • Livanova USA, Inc.$546
  • AstraZeneca$458
  • plus $7K from 54 others

What the payments were for

  • Speaking & faculty fees$190%
  • Travel & lodging$2382%
  • Food & beverage$11,96498%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AbbVie(2 entities)174$1,801
MDD US Operations, LLC4$788
Novartis44$621
UCB, Inc.23$607
Livanova USA, Inc.3$546
AstraZeneca(2 entities)19$458
TG Therapeutics, Inc.8$417
Averitas Pharma Inc.13$416
Sanofi10$376
Biogen21$352
Jazz Pharmaceuticals Inc.12$299
Lundbeck LLC10$297
Teva Pharmaceuticals USA, Inc.14$269
Eisai Inc.12$244
Neurocrine Biosciences, Inc.10$222
Pfizer10$199
Greenwich Biosciences, Inc.5$193
Bristol Myers Squibb10$192
Acadia Pharmaceuticals Inc8$192
Amneal Pharmaceuticals LLC10$182
SK Life Science, Inc.8$169
Amgen8$167
Mallinckrodt Hospital Products Inc.6$163
Catalyst Pharmaceuticals, Inc.8$162
Johnson & Johnson(2 entities)7$160
Neurelis, Inc.5$159
E.r. Squibb & Sons, L.L.C.4$158
Merz Pharmaceuticals, LLC7$147
Lilly USA, LLC7$132
CSL Behring5$126
Biohaven Pharmaceuticals, Inc.7$126
EMD Serono, Inc.3$118
Ipsen Biopharmaceuticals, Inc5$112
Tanabe Pharma America, Inc.5$101
Alnylam Pharmaceuticals Inc.4$99
Supernus Pharmaceuticals, Inc.5$97
Sunovion Pharmaceuticals Inc.7$97
Argenx US, Inc.4$94
Sumitomo Pharma America, Inc.5$75
ANI Pharmaceuticals, Inc.5$75
Biohaven Pharmaceutical Holding Company Ltd.4$74
Avanir Pharmaceuticals, Inc.3$59
Takeda Pharmaceuticals U.S.A., Inc.2$53
Acorda Therapeutics, Inc3$53
Otsuka America Pharmaceutical, Inc.3$53
Kyowa Kirin, Inc.3$50
Banner Life Sciences, LLC2$47
Axsome Therapeutics, Inc.2$47
Upsher-smith Laboratories LLC2$44
Xeris Pharmaceuticals, Inc.2$42
Octapharma USA, Inc.2$42
Vanda Pharmaceuticals Inc.2$36
Merck2$33
GRT US Holding, Inc.2$32
Abbott2$32
Aquestive Therapeutics, Inc.2$30
Scilex Pharmaceuticals Inc.1$24
Cycle Pharmaceuticals Inc1$24
GE HealthCare1$23
Aprecia Pharmaceuticals, LLC1$22

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$12,221 in reported general payments places this provider in the 95th percentile of 7,441 physician assistant providers in North Carolina.

See all physician assistant providers in North Carolina

Medicare billing

Part B allowed, 2024
$77,746
Medicare patients
513
Services billed
2,536

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
PanzygaImmun Glob G(Igg)-Ifas/Glycine16$399,759
SkyclarysOmaveloxolone12$387,212
VumerityDiroximel Fumarate24$218,903
UbrelvyUbrogepant127$177,153
Plegridy PenPeginterferon Beta-1a14$114,676
Nurtec OdtRimegepant Sulfate89$111,449
QuliptaAtogepant74$83,623
Emgality PenGalcanezumab-Gnlm94$75,998
TopamaxTopiramate23$75,206
EpidiolexCannabidiol (Cbd)17$74,732
Aimovig AutoinjectorErenumab-Aooe72$65,714
ZonegranZonisamide12$43,915
AptiomEslicarbazepine Acetate17$42,628
VimpatLacosamide18$38,958
Topiramate ErTopiramate24$38,604

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
BiogenSkyclarys, Vumerity$352$606,11536 claims
PfizerPanzyga, Nurtec Odt$199$511,208105 claims
AbbVieUbrelvy, Qulipta$1,801$260,775201 claims
UCB, Inc.Vimpat, Briviact$607$76,16443 claims
Amneal Pharmaceuticals LLCRytary, Pyridostigmine Bromide$182$48,51197 claims
Sunovion Pharmaceuticals Inc.Aptiom$97$42,62817 claims
Avanir Pharmaceuticals, Inc.Nuedexta$59$37,26323 claims
Eisai Inc.Fycompa$244$22,71918 claims
SK Life Science, Inc.Xcopri$169$15,39312 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 7,441 physician assistant providers in North Carolina.

Other physician assistant in Asheville

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →